Previous 10 | Next 10 |
-- CB-010 ANTLER Phase 1 trial in r/r B-NHL ongoing with update planned for H2 2023 -- -- CB-011 CaMMouflage Phase 1 trial in r/r MM recruiting patients at dose level 1 -- -- CB-012 IND-enabling studies initiated; IND submission in r/r AML planned for H2 2023 -- -- $317.0 ...
BERKELEY, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, is scheduled to participate in...
SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in Caribou Biosciences, Inc. (NASDAQ: CRBU) shares. Investors who suffered losses in excess of $200,000 with shares of Caribou Biosciences, Inc. (NASDAQ: CRB...
Summary Proof of concept established from the phase 1 ANTLER study in using Dose level 1 of CB-010 for the treatment of patients with relapsed/refractory B-cell NHL. Additional results from the phase 1 ANTLER study using CB-010 for the treatment of patients with relapsed/refractory B-ce...
BERKELEY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, is scheduled to present a corpora...
Caribou Biosciences ( NASDAQ: CRBU ) is down 10% Monday morning after reporting 12-month phase 1 data for CB-010, its allogeneic anti-CD19 CAR-T cell therapy candidate . Data from a cohort of six patients with B cell non-Hodgkin lymphoma showed that half maintained a durab...
-- Long-term durability observed for CB-010 allogeneic cell therapy at dose level 1 in ANTLER trial for r/r B-NHL -- -- ANTLER trial enrolling patients at dose level 3 -- BERKELEY, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clin...
-- Data supporting selection of ROR1 for CB-020 and armoring strategies for Caribou’s CAR-NK cell platform to be presented at AACR-JCA Conference today -- -- Caribou is using its chRDNA next-gen CRISPR technology to engineer and advance both CAR-NK and CAR-T cell therapy progra...
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 1, 2022 – USA News Group – A series of new Fast Track designations have been handed out by the United States Food and Drug Administration (FDA) this week, causing a flurry...
-- RMAT and Fast Track designations follow CB-010’s durable complete responses at dose level 1 in the ANTLER Phase 1 trial -- -- CB-010 is the 1 st allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout -- BERKELEY, CA, Nov. 29, 2022 (GLOBE N...
News, Short Squeeze, Breakout and More Instantly...
Caribou Biosciences Inc. Company Name:
CRBU Stock Symbol:
NASDAQ Market:
Caribou Biosciences Inc. Website:
2024-06-04 08:30:04 ET H.C. Wainwright analyst issues BUY recommendation for CRBU on June 4, 2024 06:46AM ET. The previous analyst recommendation was Buy. CRBU was trading at $2.145 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 22.3% to $0.12231 on volume of 147,748,197 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 11.8% to $0.6524 on volume of 95,235,738 shares AMC Entertainment Holdings Inc. Class A (AM...
-- CB-010 allogeneic CAR-T cell therapy w ith partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles) -- -- Plan to...